Abstract

Background:

The majority of current pharmacological treatments for Parkinson’s disease (PD) were approved for clinical use in the second half of the last century and they only provide symptomatic relief. Derivatives of these therapies continue to be explored in clinical trials, together with potentially disease modifying therapies that can slow, stop or reverse the condition.

Objective:

To provide an overview of the pharmacological therapies— both symptomatic and disease modifying— currently being clinically evaluated for PD, with the goal of creating greater awareness and opportunities for collaboration amongst commercial and academic researchers as well as between the research and patient communities.

Methods:

We conducted a review of clinical trials of drug therapies for PD using trial data obtained from the ClinicalTrials.gov database and performed a breakdown analysis of studies that were active as of January 21, 2020.

Results:

We identified 145 registered and ongoing clinical trials for therapeutics targeting PD, of which 51 were Phase 1 (35% of the total number of trials), 66 were Phase 2 (46% ), and 28 were Phase 3 (19% ). There were 57 trials (39% ) focused on long-term disease modifying therapies, with the remaining 88 trials (61% ) focused on therapies for symptomatic relief. A total of 50 (34% ) trials were testing repurposed therapies.

Conclusion:

There is a broad pipeline of both symptomatic and disease modifying therapies currently being tested in clinical trials for PD.

中文翻译：

---

临床试验管道中的帕金森病药物治疗：2020。

摘要

背景：

目前帕金森病 (PD) 的大多数药物治疗在上个世纪下半叶被批准用于临床，它们只能缓解症状。在临床试验中继续探索这些疗法的衍生物，以及可以减缓、停止或逆转病情的潜在疾病改善疗法。

目标：

概述目前正在对 PD 进行临床评估的药物疗法（包括症状和疾病改善），目的是提高商业和学术研究人员之间以及研究和患者社区之间的合作意识和机会。

方法：

我们使用从 ClinicalTrials.gov 数据库获得的试验数据对 PD 药物疗法的临床试验进行了审查，并对截至 2020 年 1 月 21 日有效的研究进行了细分分析。

结果：

我们确定了 145 项针对 PD 治疗的注册和正在进行的临床试验，其中 51 项为 1 期（占试验总数的 35%），66 项为 2 期（46%），28 项为 3 期（19%）。有 57 项试验 (39% ) 侧重于长期疾病改善疗法，其余 88 项试验 (61% ) 侧重于缓解症状的疗法。共有 50 项（34%）试验正在测试重新调整用途的疗法。

结论：

目前在 PD 的临床试验中，有广泛的对症和疾病改善疗法正在测试中。